- Home
- EVAC vs AUTL Comparison
EVAC vs AUTL Comparison
Compare EVAC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$10.25
HOLD
Current Price
$2.11
Company Overview
Basic Information| Metric | EVAC | AUTL |
|---|---|---|
| Founded | 2024 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | 752 |
| Industry | Fluid Controls | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 592.7M | 532.3M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | EVAC | AUTL |
|---|---|---|
| Price | $10.25 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 89.3K | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $9.90 | $1.18 |
| 52 Week High | $10.29 | $2.52 |
Technical Indicators
Market Signals| Indicator | EVAC | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 67.96 | 70.85 |
| Support Level | $9.99 | $1.31 |
| Resistance Level | N/A | $2.07 |
| Average True Range (ATR) | 0.01 | 0.13 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 66.67 | 88.57 |
Price Performance
Historical Comparison EVAC
AUTL
About EVAC EQV Ventures Acquisition Corp. II Class A Ordinary Shares
EQV Ventures Acquisition Corp II is a blank check company.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.